Skip To Main Content
Development Expenses on Muck Rack

Development Expenses

As seen in: Benzinga, ADVFN, MarketScreener, Comdirect Informer, Stockwatch, tradegate.de, Sparda-Bank web.Börsenforum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Development Expenses’s profile

Articles by Development Expenses

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

|
By Protalix BioTherapeutics, Stockholders' Equity, Development Expenses
| Stockwatch
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1...
Open in Who Shared View Duplicates (44) Issue with article?

Veralto Reports Second Quarter 2026 Results

|
By Development Expenses
| Stockwatch
WALTHAM, Mass., July 28, 2026 /PRNewswire/ -- Veralto (NYSE: VLTO) (the "Company"), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital Resources™, announced results for the second quarter ended July 3, 2026.
Open in Who Shared View Duplicates (109) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Space workforce, Development Expenses, IFRS Rules
| Sparda-Bank web.Börsenforum
Airbus reports Half-Year (H1) 2026 results EQS-Ad-hoc: Airbus SE / Key word(s): Half Year Results Airbus reports Half-Year (H1) 2026 results 29-Jul-2026 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (23) Issue with article?

Ceva, Inc. Announces First Quarter 2026 Financial Results

|
By Development Expenses, Its Subsidiaries, Stockholders' Equity
| Stockwatch
Highlights strong licensing growth driven by integrated solutions and accelerating edge AI adoption ROCKVILLE, Md., May 11, 2026 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, today announced its financial results for the first quarter ended March 31, 2026.
Open in Who Shared View Duplicates (74) Issue with article?

Veralto Reports First Quarter 2026 Results

|
By Development Expenses
| Stockwatch
WALTHAM, Mass., April 28, 2026 /PRNewswire/ -- Veralto (NYSE: VLTO) (the "Company"), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital Resources™, announced results for the first quarter ended April 3, 2026.
Open in Who Shared View Duplicates (138) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, IFRS Rules, Tradegate BSX
| Sparda-Bank web.Börsenforum
Airbus SE: Airbus reports First Quarter (Q1) 2026 results EQS-Ad-hoc: Airbus SE / Key word(s): Quarter Results Airbus SE: Airbus reports First Quarter (Q1) 2026 results 28-Apr-2026 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (18) Issue with article?
|
By Development Expenses, Cash Equivalents
| chase.com
Intelligent Living Application Group Inc. Announces First Half 2025 Unaudited Financial Results 6:01 PM EST 12/22/2025 - Comtex HONG KONG, Dec. 22, 2025 /PRNewswire via COMTEX News Network/ -- Intelligent Living Application Group Inc. (Nasdaq: ILAG) (the "Company" or "Intelligent Living"), a premium lockset manufacturer and distributor headquartered in Hong Kong, today announced its unaudited financial results for the six months ended June 30, 2025.
Open in Who Shared View Duplicates (88) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Space workforce, Development Expenses, IFRS Rules, Tradegate Exchange
| Sparda-Bank web.Börsenforum
Airbus SE: Airbus reports Nine-Month (9m) 2025 results EQS-Ad-hoc: Airbus SE / Key word(s): Miscellaneous Airbus SE: Airbus reports Nine-Month (9m) 2025 results 29-Oct-2025 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (18) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Space workforce, Development Expenses, IFRS Rules, Tradegate Exchange
| Sparda-Bank web.Börsenforum
Airbus SE: Airbus reports Half-Year (H1) 2025 results EQS-Ad-hoc: Airbus SE / Key word(s): Half Year Results Airbus SE: Airbus reports Half-Year (H1) 2025 results 30-Jul-2025 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (14) Issue with article?

Berliner Volksbank eG

|
By Development Expenses, IFRS Rules, Tradegate Exchange, Space workforce
| Sparda-Bank web.Börsenforum
EQS-Ad-hoc: Airbus SE / Key word(s): Quarter Results Airbus SE: Airbus reports First Quarter (Q1) 2025 results 30-Apr-2025 / 17:35 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (15) Issue with article?

EQS-Adhoc: Airbus SE: Airbus reports Nine-Month (9m) 2024 results (d.., 30.10.2024

|
By Space division.", Development Expenses, IFRS Rules
| Comdirect Informer
Airbus SE: Airbus reports Nine-Month (9m) 2024 results ^ EQS-Ad-hoc: Airbus SE / Schlagwort(e): 9-Monatszahlen Airbus SE: Airbus reports Nine-Month (9m) 2024 results 30.10.2024 / 17:45 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Open in Who Shared View Duplicates (38) Issue with article?

Airbus SE: Airbus reports Nine-Month (9m) 2024 results

|
By Space division.", Development Expenses, IFRS Rules
| MarketScreener
Open in Who Shared Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, IFRS Rules, Tradegate Exchange
EQS-Ad-hoc: Airbus SE / Key word(s): Quarter Results Airbus reports First Quarter (Q1) 2024 results 25-Apr-2024 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (18) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, IFRS Rules, Tradegate Exchange
| Sparda-Bank web.Börsenforum
EQS-Ad-hoc: Airbus SE / Key word(s): Annual Results Airbus reports Full-Year (FY) 2023 results 15-Feb-2024 / 06:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (19) Issue with article?

Brandshield Systems PLC Half year results for 6 months ended 30 June 2023 (9709M)

|
By Development Expenses, Cash Equivalents, Other payables
| ADVFN
Brandshield Systems (LSE:BRSD) Intraday Stock Chart Tuesday 19 September 2023 TIDMBRSD RNS Number : 9709M Brandshield Systems PLC 19 September 2023 19 September 2023 BrandShield Systems plc ("BrandShield," the "Company," or the "Group") Half year results for the six months ended 30 June 2023 Annualised Recurring Revenue, up 45% in H1 2023, continues to underpin operational progress BrandShield Systems plc (AIM: BRSD), a leading provider of cybersecurity solutions for brand oriented digital...
Open in Who Shared View Duplicates (4) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, IFRS Rules, acquisitions. It, Tradegate Exchange
| Sparda-Bank web.Börsenforum
EQS-Ad-hoc: Airbus SE / Key word(s): 9 Month figures Airbus reports Nine-Month (9m) 2023 results 08-Nov-2023 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (15) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, IFRS Rules, acquisitions. It, Tradegate Exchange
| Sparda-Bank web.Börsenforum
Nachrichtendetail 26.07.2023 17:45:40 - dpa-AFX: EQS-Adhoc: Airbus reports Half-Year (H1) 2023 results (english) EQS-Ad-hoc: Airbus SE / Key word(s): Half Year Results Airbus reports Half-Year (H1) 2023 results 26-Jul-2023 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (18) Issue with article?

Titon Holdings PLC Interim results for the six months to 31 Mar 2023

|
By Development Expenses, Europe USA
| ADVFN
Titon (LSE:TON) Intraday Stock Chart Friday 19 May 2023 TIDMTON RNS Number : 9417Z Titon Holdings PLC 19 May 2023 19 May 2023 LEI: 213800ZHXS8G27RM1D97 THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
Open in Who Shared Issue with article?

KRYSTAL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | MarketScreener

|
By Jeune Aesthetics, Development Expenses
| MarketScreener
The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 27, 2023.
Open in Who Shared View Duplicates (3) Issue with article?

MKS INSTRUMENTS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) | MarketScreener

|
By Development Expenses, productivity. We, Usd Libor
| MarketScreener
(MKSI) Real-time Estimate Cboe BZX - 03:42:35 2023-05-05 pm EDT 88.67 USD +5.35% 03:34p MKS INSTRUMENTS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Open in Who Shared Issue with article?

ALECTOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | MarketScreener

|
By Development Expenses
| MarketScreener
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.
Open in Who Shared Issue with article?

AGIOS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener

|
By Management's Discussion, As Well, Development Expenses
| MarketScreener
Forward-looking Information The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management's Discussion and Analysis of Financial Condition and...
Open in Who Shared Issue with article?

VAXXINITY, INC. Management's Discussion and Analysis of Financial (form 10-K) | MarketScreener

|
By During The, Capital Resources, Short-term Investments, Development Expenses
| MarketScreener
(VAXX) Delayed Nasdaq - 04:00:00 2023-03-24 pm EDT 2.150 USD +2.87% 07:31a VAXXINITY, INC. Management's Discussion and Analysis of Financial (form 10-K) AQ 03/21 Vaxxinity Joins TransCelerate Research and Development Consortium GL 03/20 Vaxxinity Says First Subjects Dosed in Phase 1 Trial of VXX-401 Vaccine Candidate to Lower Cholesterol MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?

X4 PHARMACEUTICALS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) | MarketScreener

|
By Development Expenses, Administrative expenses, Restated Loan, with Hercules
| MarketScreener
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and the other financial information included elsewhere in this Annual Report.
Open in Who Shared Issue with article?

SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) | MarketScreener

|
By Development Expenses
| MarketScreener
(SANA) Delayed Nasdaq - 04:00:01 2023-03-16 pm EDT 3.260 USD -4.68% 04:30p SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Open in Who Shared Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Development Expenses, Tradegate Exchange, IFRS Rules, acquisitions. It
| Sparda-Bank web.Börsenforum
Nachrichtendetail 03.05.2023 17:45:46 - dpa-AFX: EQS-Adhoc: Airbus reports First Quarter (Q1) 2023 results (english) EQS-Ad-hoc: Airbus SE / Key word(s): Quarter Results Airbus reports First Quarter (Q1) 2023 results 03-May-2023 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (14) Issue with article?

TRUECAR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) | MarketScreener

|
By Will Continue, Development Expenses
| MarketScreener
(TRUE) Delayed Nasdaq - 04:00:00 2023-02-23 pm EST 2.690 USD -4.27% 06:06a TRUECAR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) AQ 02/23 Transcript : TrueCar, Inc., Q4 2022 Earnings Call, Feb 23, 2023 CI 02/23 Truecar : Q4 Earnings Snapshot AQ Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?

SPS COMMERCE INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) | MarketScreener

|
By Administrative expenses, Development Expenses, "Management's Discussion
| MarketScreener
(SPSC) Delayed Nasdaq - 04:00:01 2023-02-21 pm EST 150.12 USD -1.15% 05:08p Insider Sell: Sps Commerce MT 05:08p Insider Sell: Sps Commerce MT 04:56p SPS COMMERCE INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) AQ Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?

CARLISLE COMPANIES INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) | MarketScreener

|
By Administrative expenses, Development Expenses, Carlisle Weatherproofing, Carlisle Fluid
| MarketScreener
(CSL) Real-time Estimate Cboe BZX - 03:21:14 2023-02-16 pm EST 260.65 USD +0.23% 02:25p CARLISLE COMPANIES INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) AQ 02/16 CARLISLE COMPANIES INCORPORATED : Ex-dividend day for FA 02/13 Insider Sell: Carlisle Companies MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?

ALBEMARLE CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) | MarketScreener

|
By Development Expenses, "Long-term Debt, Financing Expenses, Other Intangibles
| MarketScreener
(ALB) Real-time Estimate Cboe BZX - 05:38:33 2023-02-15 pm EST 274.57 USD +1.43% 05:34p ALBEMARLE CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) AQ 05:19p Albemarle : Name of each exchange on which registered - Form 8-K PU 05:18p Albemarle's lithium sales jump fivefold despite price hikes RE Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?

IMMUNOVANT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | MarketScreener

|
By Development Expenses, Total Batoclimab, Batoclimab program-specific research, Unallocated research
| MarketScreener
You should read the following discussion and analysis of our financial condition and results of operations together with our (1) unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q ("Quarterly Report"), and (2) audited consolidated financial statements and the related notes thereto and management's discussion and analysis of financial condition and results of operations for the fiscal year ended March 31,...
Open in Who Shared Issue with article?

DOW INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) | MarketScreener

|
By See Part II, Performance Materials, Development Expenses
| MarketScreener
(DOW) Real-time Estimate Cboe BZX - 01:10:56 2023-02-01 pm EST 59.24 USD -0.19% 07:30a DOW INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) AQ 01/31 Dow Inc.
Open in Who Shared Issue with article?

Viela Bio, Inc. (FormUPLOAD)

|
By Development Expenses, LastNameZhengbin Yao, HH RSV-MIM Holdings, Ph.D. Sincerely
| Benzinga
View PDF Filing TEXT-EXTRACT 2 filename2.txt July 16, 2019 Zhengbin Yao, Ph.D. Chairman, President and Chief Executive Officer Viela Bio, Inc. One Meddimune Way First Floor, Area Two Gaithersburg, MD 20878 Re: Viela Bio, Inc. Draft Registration Statement on Form S-1 Submitted June 17, 2019 CIK No. 0001734517 Dear Dr. Yao: We have reviewed your draft registration statement and have the following comments.
Open in Who Shared View Duplicates (2) Issue with article?

IGM Biosciences, Inc. (FormUPLOAD)

|
By Development Expenses
| Benzinga
View PDF Filing TEXT-EXTRACT 2 filename2.txt July 25, 2019 Fred Schwarzer Chief Executive Officer and President IGM Biosciences, Inc. 325 E. Middlefield Road Mountain View, CA 94043 Re: IGM Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted June 28, 2019 CIK No. 0001496323 Dear Mr. Schwarzer: We have reviewed your draft registration statement and have the following comments.
Open in Who Shared Issue with article?

Arcturus Therapeutics Ltd. (FormUPLOAD)

|
By Development Expenses
| Benzinga
View PDF Filing TEXT-EXTRACT 2 filename2.txt August 6, 2019 Joseph E. Payne President, Chief Executive Officer and Director Arcturus Therapeutics Ltd. 10628 Science Center Drive Suite 250 San Diego, California 92121 Re: Arcturus Therapeutics Ltd. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 18, 2019 File No. 001-35932 Dear Mr. Payne: We have reviewed your filing and have the following comment.
Open in Who Shared Issue with article?
Show More